Australia markets close in 26 minutes
  • ALL ORDS

    6,859.20
    +87.20 (+1.29%)
     
  • ASX 200

    6,649.00
    +87.40 (+1.33%)
     
  • AUD/USD

    0.7314
    +0.0027 (+0.37%)
     
  • OIL

    43.48
    +0.42 (+0.98%)
     
  • GOLD

    1,821.80
    -16.00 (-0.87%)
     
  • BTC-AUD

    25,055.78
    -75.10 (-0.30%)
     
  • CMC Crypto 200

    368.13
    +6.70 (+1.85%)
     
  • AUD/EUR

    0.6171
    +0.0019 (+0.31%)
     
  • AUD/NZD

    1.0493
    -0.0033 (-0.31%)
     
  • NZX 50

    12,553.38
    +51.64 (+0.41%)
     
  • NASDAQ

    11,905.94
    -0.50 (-0.00%)
     
  • FTSE

    6,333.84
    -17.61 (-0.28%)
     
  • Dow Jones

    29,591.27
    +327.79 (+1.12%)
     
  • DAX

    13,126.97
    -10.28 (-0.08%)
     
  • Hang Seng

    26,498.67
    +12.47 (+0.05%)
     
  • NIKKEI 225

    26,225.89
    +698.52 (+2.74%)
     

Rubius Therapeutics to Announce Third Quarter 2020 Financial Results

Rubius Therapeutics
·1-min read

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced plans to report third quarter 2020 financial results on Monday, November 9, 2020, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com

Media:
Marissa Hanify
Director, Corporate Communications
marissa.hanify@rubiustx.com

Dan Budwick
1AB
+1 (973) 271-6085
dan@1abmedia.com